This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.

Guardant Health, Inc.

Natera, Inc.

Adaptive Biotechnologies Corporation

Krystal Biotech, Inc.

Ligand Pharmaceuticals Incorporated

Twist Bioscience Corporation

BridgeBio Pharma, Inc.

Medpace Holdings, Inc.

Vertex Pharmaceuticals Incorporated

Eli Lilly and Company

Healthcare

Financial Services

Technology

Basic Materials

Franklin Genomic Advancements ETF

HELX Holdings & Sector Breakdown